Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development -- Infectious Diseases
March 18 2015 - 8:00AM
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today the
appointment of Scott M. White, M.D. as Vice President, Clinical
Development – Infectious Diseases. Dr. White will be responsible
for advancing Inovio's infectious disease portfolio of DNA
immunotherapies and vaccines through clinical trials to
commercialization. He will report to Dr. Mark Bagarazzi, Inovio's
Chief Medical Officer.
Inovio is advancing a robust clinical pipeline of therapies and
vaccines for infectious diseases including hepatitis B and C, HIV,
influenza, Ebola and other tropical diseases.
Dr. White joins Inovio from GlaxoSmithKline where he spent more
than a decade in positions of increasing responsibility leading
global infectious disease clinical development programs. His most
recent position was Senior Director and Project Physician Leader
for skin-related infections. He led multiple programs within the
Infectious Diseases Therapy Area with international
responsibilities from clinical trials to business and market
development. In his GSK career, Dr. White built strong
relationships with the FDA, EMEA and other regulatory and
government agencies. Most notable was his leadership in the design
and implementation of a pioneering European antibacterial clinical
development network through a public private partnership between
the European Commission and EFPIA (European Federation of
Pharmaceutical Industries and Associations).
Dr. J. Joseph Kim, President & CEO of Inovio, said, "Scott
will bring to Inovio his global experience and expert judgment in
advancing infectious disease therapies and vaccines through
numerous country regulatory agencies. As we ramp up clinical
development of our rich pipeline, Inovio has now attracted three
cancer and infectious disease opinion leaders this year. Their
counsel as M.D.'s will be invaluable to Inovio as we move our
vaccines and immunotherapies closer to market."
Dr. White, who earned his M.D. at the Pennsylvania State
University College of Medicine, was an Edward J. Wing Fellow in
Infectious Diseases at the University of Pittsburgh Medical Center.
He also was assistant professor at Baylor College of Medicine and
The University of Pittsburgh School of Medicine as well as lead
author of numerous scientific publications.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania, DARPA, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com.
This press release contains certain forward-looking statements
relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, including INO-5150, and
to commence a phase I clinical trial for INO-5150 in the first half
of 2015, the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2014,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals
858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals
267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024